Chemotherapeutic response is critical for the successful treatment and good prognosis in cancer patients. In this study, we analyzed the gene expression profiles of preoperative samples from ER-negative breast cancer patients with different responses to taxane-anthracycline-based (TA-based) chemotherapy, and identified a group of genes that was predictive. Pregnancy specific beta-1-glycoprotein 1 (PSG1) played a central role within signaling pathways of these genes. Inhibiting the PSG1 can effectively reduce chemoresistance via transforming growth factor-β (TGF-β)-related pathway in ER-negative breast cancer cells. Drug screening then identified dicumarol (DCM) to target the PSG1 and inhibited chemoresistance to TA-based chemotherapy in vitro , in vivo , and in clinicalsamples. Taken together, this study highlight PSG1 as an important mediator of chemoresistance, whose effect could be diminished by DCM.
- Pregnancy specific beta-1-glycoprotein 1 (PSG1)
- ©2016 The Author(s)
This is an Accepted Manuscript; not the final Version of Record. Archiving permitted only in line with the archiving policy of Portland Press Limited. All other rights reserved.